Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: A double-blind, placebo- controlled trial

Annals of Internal Medicine

Volumn 128, Issue 1, 1998, Pages 21-28

  Schacker, Timothy ^b   Hu, Hui Lin ^c   Koelle, David M ^a   Zeh, Judith ^c   Saltzman, Robin ^d   Boon, Ron ^d   Shaughnessy, Mary ^e   Barnum, Gail ^e   Corey, Lawrence ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SmithKline Beecham   (United States)

^e Virology Research Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; PENCICLOVIR;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SERODIAGNOSIS; TISSUE CULTURE; VIRUS REACTIVATION; VIRUS SHEDDING;

EID: 0031984708     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-1-199801010-00004     Document Type: Article

References (30)

1. Siegal FP, Lopez C, Hammer GS, Brown AE, Kornfeld SJ, Gold J, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981;305: 1439-44.
2. Wentworth BB, Alexander ER. Seroepidemiology of infections due to members of the herpesvirus group. Am J Epidemiol. 1971;94:496-507.
3. Gibson JJ, Hornung CA, Alexander GR, Lee FK, Potts WA, Nahmias AJ. A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. J Infect Dis. 1990;162: 306-12.
4. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med. 1989;321:7-12.
5. Enzensberger R, Braun W, July C, Helm EB, Doerr HW. Prevalence of antibodies to human herpesviruses and hepatitis B virus in patients at different stages of human immunodeficiency virus (HIV) infection. Infection. 1991;3: 140-5.
6. Mann SL, Meyers JD, Holmes KL, Corey L. Prevalence and incidence of herpesvirus infections among homosexually active men. J Infect Dis. 1984; 149:1026-7.
7. Siegel D, Golden E, Washington AE, Morse SA, Fullilove MT, Catania JA, et al. Prevalence and correlates of herpes simplex infections. The population-based AIDS in Multiethnic Neighborhoods Study. JAMA. 1992;268: 1702-8.
8. Quinn TC, Piot P, McCormick JB, Feinsod FM, Taelman H, Kapita B, et al. Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. JAMA. 1987;257:2617-21.
9. Mertz GJ. Genital herpes simplex virus infections. Med Clin North Am. 1990; 74:1433-54.
10. Nahmias A, Lee F, Beckman-Nahmias S. Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl. 1990;69:19-36.
11. Safrin S, Arvin A, Mills J, Ashley R. Comparison of the Western immunoblot assay and a glycoprotein G enzyme immunoassay for detection of serum antibodies to herpes simplex virus type 2 patients with AIDS. J Clin Microbiol. 1992;30:1312-4.
12. Augenbraun M, Feldman J, Chirgwin K, Zenilman J, Clarke L, DeHovitz J, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med. 1995;123:845-7.
13. Bagdades EK, Pillay D, Squire SB, O'Neil C, Johnson MA, Griffiths PD. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS. 1992;6:1317-20.
14. Straus SE, Takiff HE, Seidlin M, Bachrach S, Lininger L, DiGiovanna JJ, et al. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med. 1984;310:1545-50.
15. Douglas JM, Critchlow C, Benedetti J, Mertz GJ, Connor JD, Hintz MA, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 1984;310:1551-6.
16. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med. 1996;124:8-15.
17. Boyd M, Safrin S, Kern E. Penciclovir: a review of its spectrum of activity, sensitivity, and cross-resistance pattern. Antiviral Chemistry and Chemotherapy. 1993;4(Suppl 1):3-11.
18. Wald A, Corey L, Cone R, Hobson A, Davais G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest. 1997;99:1092-7.
19. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol. 1988;26:662-7.
20. Langenberg A, Zbanyszek R, Dragavon J, Ashley R, Corey L. Comparison of diploid fibroblast and rabbit kidney tissue cultures and a diploid fibroblast microtiter plate system for the isolation of herpes simplex virus. J Clin Microbiol. 1988;26:1772-4.
21. Schmidt NJ, Emmons RW, eds. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections. Washington, DC: Am Public Health Assoc; 1989.
22. Swierkosz EM, Scholl DR, Brown JL, Jollick JD, Gleaves CA. Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus. Antimicrob Agents Chemother. 1987;31:1465-9.
23. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics. 1972;28:577-84.
24. Safrin S, Ashley R, Houlihan C, Cusick PS, Mills J. Clinical and serologic features of herpes simplex virus infection in patients with AIDS. AIDS. 1991; 5:1107-10.
25. Vere Hodge RA. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chemistry and Chemotherapy. 1993;4:67-84.
26. Hodge RA, Perkins RM. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother. 1989;33:223-9.
27. Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs. 1995;50:396-415.
28. Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother. 1993;37:2241-3.
29. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. [In press.]
30. Stanley SK, Ostrowski MA, Justement JS, Gantt K, Hedayati S, Mannix M, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996;334:1222-30.